Sep 30, 2023

Penumbra Q3 2023 Earnings Report

Penumbra reported strong Q3 2023 results with significant revenue growth and increased profitability.

Key Takeaways

Penumbra, Inc. reported a 26.8% increase in revenue to $270.9 million for Q3 2023, driven by strong growth in thrombectomy products. The company achieved a net income of $9.2 million and an adjusted EBITDA of $51.5 million.

Revenue increased by 26.8% to $270.9 million compared to Q3 2022.

Thrombectomy product sales grew by 38.0% to $179.1 million.

Net income was $9.2 million, with an adjusted EBITDA of $51.5 million.

The company expects revenue growth to accelerate to 28% to 31% year over year for Q4 2023.

Total Revenue
$271M
Previous year: $214M
+26.8%
EPS
$0.67
Previous year: $0.01
+6600.0%
Gross Margin
65.6%
Previous year: 63.3%
+3.6%
Gross Profit
$178M
Previous year: $135M
+31.3%
Cash and Equivalents
$101M
Previous year: $54.8M
+83.7%
Free Cash Flow
$27.5M
Previous year: -$19.3M
-242.9%
Total Assets
$1.47B
Previous year: $1.32B
+11.1%

Penumbra

Penumbra

Penumbra Revenue by Geographic Location

Forward Guidance

The company expects total company revenue growth to accelerate to 28% to 31% year over year for the fourth quarter of 2023, correlating to the midpoint of the annual guidance range of $1.05 billion to $1.07 billion for full year 2023.

Revenue & Expenses

Visualization of income flow from segment revenue to net income